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Abstract:  
 
Research into antibacterial agents has recently gathered pace in 
light of the disturbing crisis of antimicrobial resistance. 
Development of modern tools offers opportunity of reviving the 
fallen era of antibacterial discovery through uncovering novel 
lead compounds that target vital bacterial cell components, such 
as lipid II. This paper provides a summary of the role of lipid II as 
well as an overview and insight into the structural features of 
macrocyclic peptides that inhibit this bacterial cell wall 
component. The recent discovery of teixobactin, a new class of 
lipid II inhibitor has generated substantial research interests. As 
such, the significant progress that has been achieved towards its 
development as a promising antibacterial agent is discussed. 
 
1. Introduction 
 
1.1. Past, present and future of antibiotics  
 
For centuries, bacterial infections have troubled mankind and 
their history could be traced all the way back to ancient Egypt. 
Mouldy jam and bread were often used in folk medicine as 
poultice on wounds without understanding the antibacterial 
nature of moulds.[1] In 1930s, the discovery of penicillin by 
Alexander Fleming heralded the dawn of a new era for 
controlling previously fatal bacterial infections, saving numerous 
lives.[2] Intensive research soon followed that led to the 
discovery of other antibiotics, such as streptomycin and 
tetracycline.[3–5] However, as predicted by Paul Ehrlich, 
resistance tends to follow a medicine development like a “faithful 
shadow”.[6] The widespread misuse of antibacterial agents have 
contributed to the emergence of resistant bacterial strains within 
just a few years after their clinical introduction.[5–8]  
Antimicrobial resistance (AMR), which could be either 
intrinsic or acquired, remains an increasingly serious global 
threat with far-reaching clinical and cost implications.[3,9] 
Clinically important antibiotic-resistant pathogens include 
Staphylococcus aureus, Pseudomonas aeruginosa and 
Enterococcus faecium.[10] Treatment failure and prolonged 
illnesses inevitably lead to greater healthcare expenditure and 
higher mortality rate.[11] On top of that, significant medical 
breakthroughs such as organ transplantation and invasive 
surgeries which rely heavily on the use of antibiotics are now 
threatened by AMR.[12] A recent evaluation of this crisis has 
estimated that AMR would lead to 300 million premature death 
and a global economic cost of $100 trillion over the next three 
decades.[13,14]  
Unfortunately, the situation is further complicated by a 
decline in the introduction of novel antibiotics (Figure 1).  The 
“golden age” (1940s – 1960s) saw the discovery of most of the 
antibiotics in clinic today through exploitation of cultivable soil 
microbes (Waksman platform).[15,16] However, this era crumbled 
by the end of 1960s as no new compounds with significantly 
different molecular scaffold and/or mechanism-of-action from 
existing agents were uncovered from this limited resource of soil 
bacteria.[14,17] Scientists began to employ synthetic approaches 
but bacterial cell envelopes have proven to be a huge hurdle for 
the synthetic compounds.[16,18] Attempts to overcome cell 
membrane penetration and efflux issues by formulating 
sophisticated drug delivery systems have not yielded 
satisfactory clinical results.[12] The unfavourable financial return 
eventually caused pharmaceutical companies to shift their 
research focus to other diseases.[10,14] As feared by scientific 
community and healthcare professionals, the post-antibiotic age 
may now be upon us with the detection of pathogenic bacterial 
strains being resistant to colistin, the last antibiotic on the 
shelf.[12] 
Figure 1. Antibiotic discovery timeline showing the golden era and the gap 
where no new structurally or functionally distinct antibiotics were found.[7,18] 
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Despite the seemingly discouraging circumstances, Ling et al. 
brought exciting news to address this global predicament 
through their work on uncultured bacteria.[16] Over 99% of soil 
bacteria in nature are uncultured which reflects their inability to 
grow on laboratory media.[19] These microbes thus represent an 
untapped reservoir of valuable compounds.[18,20] A multichannel 
device known as the isolation chip (iChip)[21] was utilised by the 
research group to isolate and grow individual bacterial cell in 
miniature chambers. Prior to returning it to the soil, the device 
was covered with two semi-permeable membranes so that the 
cells could receive the environmental nutrients and growth 
factors needed for viability. Following incubation, the bacterial 
colonies were grown in vitro and their extracts were screened for 
antibacterial activity. The hard work paid off with the discovery of 
teixobactin which is isolated from a newly identified Gram-
negative β-proteobacteria, Eleftheria terrae.[14,16,20,22,23] 
Significantly, teixobactin is a potent inhibitor of lipid II, an 
essential component for the bacterial biosynthesis of cross-
linked peptidoglycan.[16] 
Therefore, all is not lost in the battle against bacterial 
infections as modern tools offer great opportunity to revive the 
old ways of discovering therapeutic compounds from the huge 
diversity of soil microorganisms.[18,21] This mini-review thus 
provides an overview and an update on different classes of lipid 
II-targeting peptide antibiotics, particularly their chemical and 
structural aspects, as they are likely to revolutionise the 
treatment of bacterial infections.   
 
2. Targeting the central component of 
peptidoglycan synthesis 
 
2.1 Bacterial cell wall synthesis 
 
Bacterial cell wall, a unique structure crucial for cell survival and 
integrity, has long been validated as a prominent target for 
antimicrobials.[24,25] Its main structural component known as 
peptidoglycan provides bacteria with the mechanical strength to 
withstand high intracellular osmotic pressure.[26,27] Peptidoglycan 
is a polymer made up of linear chains of alternating N-
acetylglucosamine (GlcNAc) and N-acetylmuramic acid 
(MurNAc) amino sugars coupled together by a β-1,4-glycosidic 
bond.[28] A pentapeptide domain, the sequence of which 
depends on the species of bacteria, is attached to the N-terminal 
carboxyl moiety of the MurNAc sugar.[29–31] The pentapeptide L-
Ala-D-γ-Glu-L-Lys-D-Ala-D-Ala is typically present in most Gram-
positive pathogens.[30,32,33] Cross-linking of the glycan chains is 
then achieved through sidechain-to-backbone amide bond 
formation between strands of pentapeptide domains.[34–36]  
Bacterial cell wall biosynthesis is highly complex, with 
multiple components and numerous tightly coordinated 
enzymatic reactions (Figure 2).[34] The two-stage process of 
peptidoglycan subunit synthesis begins with the assembly of 
UDP-MurNAc-pentapeptide precursor from UDP-GlcNAc 
through a series of steps catalysed by MurA-F synthetases in 
cytoplasmic side.[29] UDP-MurNAc-pentapeptide is then 
transferred by MraY translocase to the 11-subunit membrane-
embedded undecaprenyl phosphate, thereby producing an 
intermediate called lipid I. Following the coupling of GlcNAc to 
lipid I, lipid II is formed which carries the complete peptidoglycan 
subunit (GlcNAc-MurNAc-pentapeptide) that is attached to 
undecaprenyl phosphate via a pyrophosphate moiety.[27,30,34] 
During the second stage, lipid II is flipped by MurJ or FtsW 
flippase to the periplasmic side of inner membrane.[29,37,38] 
Subsequently, lipid II is incorporated into growing cell wall 
through transglycosylation and transpeptidation reactions 
catalysed by the two catalytic domains of penicillin-binding 
proteins (PBPs).[35,39] The released undecaprenyl pyrophosphate 
is then shuttled back to the cytosolic face where it is 
dephosphorylated back into its monophosphate form to be 
recycled for the next synthesis cycle.[27,34,40]  
Figure 2. Bacterial cell wall synthesis involves a complex series of enzymatic 
reactions. Lipid I is produced when the assembled UDP-MurNAc-pentapeptide 
is attached to the membrane-embedded undecaprenyl phosphate. Another 
UDP-GlcNAc molecule is transferred to lipid I, thus forming lipid II which is 
then flipped across the membrane to the periplasmic face where it can be 
incorporated into the peptidoglycan layer through transglycosylation and 
transpeptidation reactions.    
 
2.2 Lipid II as the therapeutic target 
 
Among the cell wall components, lipid II is one of the most highly 
sought-after targets for antimicrobials (Figure 3).[34,41] Despite 
being an essential peptidoglycan precursor, a limited amount of 
lipid II can be synthesised at a time since there are only 
approximately 2 x 105 undecaprenyl phosphate molecules 
present in each cell.[30,42,43] To keep up with the rapid growth of 
peptidoglycan layer, each lipid II molecule must have a high 
turnover rate.[44] The lipid II cycle is thus considered to be the 
rate-limiting step in peptidoglycan biosynthesis, thereby making 
this lipid intermediate an attractive antibiotic target.[30,45] 
Figure 3. The chemical structure of lipid II (1) and binding sites of several lipid 
II inhibitors. The pentapeptide sequence in Gram-positive bacteria is shown.  
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The localisation of lipid II on the outside of bacterial 
cytoplasmic membrane allows it to be easily targeted by 
antimicrobial agents. In addition, its structural complexity offers 
several potential binding sites for antibiotics.[27] The 
pentapeptide domain apparently adopts an upright position and 
points away from the surface of phospholipid bilayer.[44] 
Meanwhile, the anchoring of its undecaprenyl phosphate in the 
membrane strategically places the negatively-charged 
pyrophosphate at the bilayer interface where ionic interactions 
with positively-charged residues or compounds can be easily 
formed.[17] These groups therefore serve as attractive binding 
motifs for lipid II inhibitors.[44] Furthermore, lipid II composition is 
unique within the bacterial kingdom, thereby preventing possible 
toxic effect of lipid II binders on mammalian cells.[27,46,47]  
Research with lipid II was initially restricted by its low 
abundance and the laborious isolation and purification 
processes involved.[48,49] However, the availability of membrane 
enzymes and the attractiveness of lipid II as an antimicrobial 
target have driven the development of chemical, 
chemoenzymatic and enzymatic strategies to prepare lipid II.[50–
53] The enzymatic approach utilises MraY and MurG activities of 
membrane preparations to synthesise lipid II in the presence of 
undecaprenyl phosphate, UDP-MurNAC-pentapeptide and UDP-
GlcNAc. As both enzymes have narrow substrate specificity, this 
method is highly effective and can be easily scaled up.[50,53,54] On 
the other hand, chemical synthesis enables various structural 
alterations of lipid II that cannot be achieved with MraY and 
MurG.[51,52] Its main drawback is the costly chemical reagents. 
Alternatively, a combination of chemical and enzymatic 
procedures can be utilised whereby purified MurG is used to 
convert chemically-synthesised lipid I to lipid II.[54,55] The 
development of these methods for the preparation of lipid II 
facilitates the identification and detailed studies of lipid II 
inhibitors; the choice of preparation of lipid II relies primarily on 
the lipid II variant that is needed.[54] The interaction of 
antibacterial agents with lipid II can then be investigated via co-
incubation of these compounds with the purified lipid II, followed 
by extraction and analysis using thin-layer chromatography.[16,56]  
 
3.  Lipid II inhibitors as therapeutic agents 
 
3.1 Progress over the last 60 years  
 
The highly dynamic lipid II is the target of several classes of 
antibiotics that home in on different parts of the 
molecule.[25,30,34,57] The first discovered example of lipid II 
inhibitor is vancomycin 2, a glycopeptide which is used as the 
last-line treatment for problematic Gram-positive organisms, 
such as methicillin-resistant S. aureus (MRSA).[58] As shown in 
Figure 4, it binds to the C-terminal D-Ala-D-Ala of the 
pentapeptide.[59,60] By forming a stable complex with lipid II 
through five hydrogen bonds and hydrophobic interactions, 
vancomycin sterically shields this lipid intermediate from PBPs 
and prevents its subsequent incorporation into the growing 
peptidoglycan network.[61,62] Bacteria eventually succumb to the 
high internal osmotic pressure due to weakened cell wall.[17] 
However, despite the initial excitement of vancomycin being 
effective against resistant bacteria when it was introduced in 
1953, vancomycin-insensitive strains have now surfaced through 
horizontal gene transfer.[22,63] The clinical resistance can be 
attributed to operons encoding proteins that mediate the 
enzymatic replacement of terminal D-Ala with D-Lac or D-Ser, 
producing low-affinity peptidoglycan building blocks.[63,64] The 
resulting D-Ala-D-Lac and D-Ala-D-Ser dipeptide motifs reduce 
the affinity of vancomycin through the loss of a crucial hydrogen 
bond and the formation of steric hindrance, respectively.[34,62,65,66] 
 
Figure 4. Hydrogen bonds (dotted lines) between vancomycin (2) and D-Ala-
D-Ala of lipid II.[62] 
 
The clinical challenges of vancomycin-resistant 
staphylococci and enterococci raised research interests into 
semisynthetic glycopeptide variants, such as oritavancin and 
telavancin, which also bind to the C-terminus dipeptide.[67,68] 
These agents, however, contain extra hydrophobic residues 
which increase their amphiphilicity.[34] For example, oritavancin 3 
carries both 4-epi-vancosamine and 4’-chlorobiphenyl methyl 
moieties that form additional interactions with the peptidyl cross 
bridge and D-γ-Gln of lipid II, thus compensating for the lost 
hydrogen bond observed in vancomycin-resistant strains (Figure 
5).[62,69] As such, oritavancin showed enhanced antibacterial 
potency against MRSA and other vancomycin-insensitive 
bacteria.[70,71] 
 
Figure 5. Chemical structure of oritavancin (3), with its extra hydrophobic side 
chains. 
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Besides that, the issue with vancomycin resistance 
revealed binding sites that are prone to mutations and 
highlighted the need for antibiotics that exploit other less 
modifiable domains of lipid II.[72] One important class of such 
agents is the lantibiotics, a group of peptides with the 
characteristic lanthionine and/or methyllanthionine moieties.[73–75] 
They can be further divided into two subtypes. Type A 
lantibiotics are elongated and positively charged whereas type B 
agents are globular compounds which are either slightly 
negatively charged or non-charged under neutral condition.[76,77] 
Nisin, a type A lantibiotic produced by Lactococcus lactis, 
has been used as natural food preservative for decades.[40,78] 
Hsu et al.[26] have shown that the first ten N-terminal amino acid 
residues of its rings A and B form a cage that envelopes the 
pyrophosphate linkage of lipid II instead of the vancomycin-
targeted pentapeptide domain. Intermolecular hydrogen bonds 
between the pyrophosphate and the amide backbone of the 
rings lock lipid II in a stable complex, thus halting the entire 
peptidoglycan synthesis.[26,34,56] The primary structure of nisin 
and its structure-activity relationship (SAR) with lipid II are 
depicted in Figure 6. However, rings A-B are inactive on their 
own.[79] It is suggested that upon pyrophosphate cage formation, 
the rings C-E (C-terminus) of nisin insert into the lipid bilayer, 
thereby facilitating the assembly of nisin-lipid II pore complex 
which leads to the lysis of bacteria.[40,80–82] This dual mechanism-
of-action makes nisin a very potent Gram-positive antibacterial 
agent. Unfortunately, the poor pharmaceutical properties of 
native nisin, such as sensitivity to proteolytic enzymes and poor 
solubility beyond pH 6, limit its clinical uses.[73,77] Semisynthetic 
analogues have been developed whereby the C-E domain of the 
natural product was replaced with various lipid substituents. 
Several of these derivatives which showed enhanced proteolytic 
stability and potent antibacterial activity hold great therapeutic 
promise.[82]  
 
 
 
 
 
 
 
Figure 6. (a) Primary structure of nisin. (b) The residues of rings A and B of 
nisin envelope the pyrophosphate group of a lipid II variant, with intermolecular 
hydrogen bonds illustrated as white dashes.[26] The solution structure of nisin-
lipid II complex was obtained from Research Collaboratory for Structural 
Bioinformatics (RCSB) Protein Data Bank (PDB ID: 1WCO) and the figure was 
generated using PyMOL (http://www.pymol.org/). Abu, aminobutyric acid; Dha, 
didehydroalanine; Dhb, didehydrobutyrine. 
The modes of action of other lantibiotics and cyclic 
peptides, such as ramoplanin and enduracidin, have been 
extensively reviewed in various literature.[17,34,83–88]  
Lipid II inhibition is also achieved by defensins, a large 
group of endogenous peptides expressed in a wide range of 
organisms. They form the host epithelial defense system.[89,90] 
For instance, Schneider et al. demonstrated that plectasin, a 
defensin isolated from a saprophytic fungus Pseufoplectania 
nigrella, disrupts cell wall biosynthesis through binding to lipid 
II.[91,92] Defensins from fungi, invertebrates such as maggots and 
mussels, and humans have shown similar antimicrobial 
activity.[46,93,94] These studies not only firmly support lipid II as a 
valuable therapeutic target, but also suggest alternative 
resources of discovering novel antibacterial agents.  
 
3.2 Teixobactin as a promising lipid II inhibitor 
 
The aforementioned teixobactin has been reported to be the first 
of a new class of lipid II inhibitors that interacts mainly with the 
pyrophosphate and first sugar moiety of the molecule. Although 
lipid II is its predominant target, teixobactin also acts on lipid III 
(undecaprenyl-pyrophosphate-GlcNAc) which plays a pivotal 
role in the synthesis of another cell wall component called 
teichoic acid.[3,16] This may lead to the release of autolysins 
which are anchored by teichoic acid under normal 
circumstances.[95] Autolysin-mediated digestion of peptidoglycan 
layers that eventually results in bacterial lysis has therefore been 
proposed as another mode of action of this antibacterial 
agent.[16,96] As such, teixobactin has demonstrated potent in vitro 
and in vivo bactericidal activity.[16]  
Structural studies have revealed teixobactin 4 as a cyclic 
tetradepsipeptide that comprises 11 amino acids, four of which 
are of D-configuration (Figure 7). Apart from N-methyl-D-
phenylalanine, it contains an unusual amino acid known as L-
allo-enduracididine. The variants of this amino acid can also be 
found in enduracidin and mannopeptimycin.[16,87,97,98] The SARs 
of teixobactin and its lipid targets, however, remain to be 
addressed. Also, there are still very little preclinical 
investigations to date for this cyclic depsipeptide and so these 
preliminary results should be interpreted with caution to avoid 
possible bias. 
Figure 7. Chemical structure of teixobactin (4), with D-amino acids (red), β-
hydroxy amino acids (green) and the unusual enduracididine highlighted (blue).  
b. 
a. 
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Its excellent activity against resistant bacterial strains and 
the lack of resistance have stimulated tremendous research 
interests in developing teixobactin into a therapeutic agent.[16] In 
less than a year after its discovery, the first total synthesis of its 
analogue by solid-phase peptide synthesis has been 
successfully executed. Here, the L-allo-enduracididine residue 
found in teixobactin is replaced with the readily available L-
Arg.[99] Intramolecular cyclisation, an intrinsically slow process 
susceptible to side-reactions such as dimerisation and 
epimerisation of α-C on C-terminus, is the main synthetic hurdle 
for all cyclic peptides.[100,101] Following careful consideration of 
cyclisation position and coupling reagents, Albericio and his co-
workers accomplished macrolactamisation of the protected 
peptide in just one day by using PyAOP/OxymaPure/DIEA 
without side-reactions (Figure 8). However, their synthetic 
attempt was not without setback. The symmetrical anhydride 
method employed for the esterification between D-Thr and L-Ile 
required several couplings to attain 97% conversion. 
Nevertheless, several problems were avoided with the 
realisation that it was necessary to couple two additional amino 
acids onto D-Thr prior to the esterification of its hydroxyl group, 
in order to prevent O→N acyl migration during deprotection of 
Fmoc from D-Thr. Undesirable formation of diketopiperazine was 
also prevented by protecting the N-terminus of both L-Ile and L-
Arg with an Alloc protecting group instead of Fmoc.[99] With 
further optimisation of the esterification step, this synthetic 
strategy would represent a significant advancement. Importantly, 
the Arg-analogue obtained displayed similar antibacterial activity 
as teixobactin.[99] Its slight inferior potency against S. aureus and 
B. subtilis compared to teixobactin must then be attributed to the 
L-Arg residue, implying that a constrained guanidino-based side 
chain with additional chirality is better than its flexible 
counterpart.  
Figure 8. Esterification and macrolactamisation performed by Albericio and his 
co-workers to obtain a teixobactin analogue. 
The remaining hurdle to the total synthesis of the natural 
product is then the availability of the unusual amino acid L-allo-
enduracididine. The presence of enduracididine in several 
prominent peptides has inspired effort to devise its synthesis 
from simple precursors.[102–104] Achieving the correct chirality at 
C4 is the primary difficulty in synthesising this amino acid.[103] 
The earliest reported strategy utilised Bamberger cleavage of 
methyl L-histidinate and subsequent hydrogenation to give a 1:1 
mixture of (2S,4R)-enduracididine and its (2S,4S)-
diastereomer.[105] Other research groups undertook alternative 
methods of synthesising the amino acid from commercially 
available allylglycine, namely one-pot iminoiodane-mediated 
tandem aziridation and ring-opening reaction, as well as Rh-
catalysed approach. However, neither diasteroselectivity nor 
yield was satisfactory.[102,104] The situation may have been turned 
around as Craig et al. have succeeded in developing a method 
with desirable stereoselectivity (dr > 50:1) and scalability. The 
required chirality of C4 was obtained through inversion of the 
hydroxyl group of trans-hydroxyproline 7 by mesylation and 
azide substitution to afford the azido-derivative 8 as shown in 
Figure 9. Although 10 steps were involved, the high 
diastereoselectivity ensured that the yield of the desired 
diastereomer was not compromised.[103]  
 
 
 
 
 
 
 
 
 
Figure 9. The key mesylation and azide substitution steps that established the 
chirality of C4. 
 
With tremendous progress in the synthetic strategies for 
enduracididine and teixobactin analogue, the total synthesis of 
the naturally occurring teixobactin would soon be within the 
grasp of scientific community.  
 
3.3.  An insight into the structures of teixobactin and other 
lipid II binders  
 
Until recently, the different classes of lipid II binders have been 
regarded as having no significant structural similarities.[17,58] 
However, a closer examination of the chemical structures of 
teixobactin (Figure 7) and other lipid II binders including 
ramoplanin A2, enduracidin A, katanosin B and plusbacin A3 
(Figure 10) showed that lipid II is generally favoured by cyclic 
peptides.[30,87,88,106,107] In contrast to linear peptides, the 
conformational restriction of cyclic structures contributes to 
better metabolic stability and improved target binding affinity.[108] 
MINIREVIEW          
 
 
 
 
 
Also, the macrocyclic peptides 10, 11 and 13 (Figure 10) 
possess lipophilic side chains which are vital for their 
antimicrobial activities, possibly through membrane insertion or 
hindering PBPs from reaching lipid II.[17,107] A noticeable 
structural difference is the unique dimannosyl group that is 
present only in ramoplanin A2 10, which is likely to provide 
enhanced hydrolytic stability and solubility.[87,109,110]  
Interestingly, in the case of mannopeptimycins, a class of 
cyclic glycopeptide isolated from Streptomyces hygroscopicus 
LL-AC98,[111] an acyl dissacharide moiety O-tethered to a 
tyrosine residue appeared to be crucial for antibacterial activity. 
Its most potent member, mannopeptimycin ε consists of a cyclic  
hexapeptide core. Importantly, its D-Tyr residue is O-
glycosylated with a dimannosyl moiety carrying an isovaleryl 
group at the C4 position of terminal mannose ring while its β-
OH-D-allo-enduracididine residue has an N-linked mannose 
group (Figure 11).[98,112–114] Singh et al. demonstrated that 
mannopeptimycin β which lacks both the isovaleryl and 
dissacharide displayed poor in vitro and in vivo activity.[111] 
Further investigations revealed that the isovaleryl moiety is also 
vital for antibacterial activity.[115] Research began to focus on 
preparation of semisynthetic analogues with modifications 
mainly on this disaccharide side chain.[113–117]. Moreover, the 
replacement of both enduracididine residues of a 
mannopeptimycin aglycone analogue with L- and D-Arg 
demonstrated a notable reduction in antimicrobial effect;[118] a 
similar detrimental effect was observed when the enduracididine 
residue in teixobactin was replaced with Arg.[99] As limited SAR 
studies are currently available, the key structural requirements of 
lipid II inhibitors remain to be established. 
 
 Figure 10. Chemical structures of ramoplanin A2 (10), enduracidin A (11), katanosin B (12), and plusbacin A3 (13), with D-amino acids (red), β-hydroxy 
amino acids (green), and enduracididine (blue) highlighted. Orn, ornithine; Hpg, 4-hydroxyphenylglycine; Dpg, 3,5-dichloro-4-hydroxyphenylglycine; Cit, 
citrulline. 
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Figure 11. Chemical structure of mannopeptimycin ε (14), showing D-amino 
acid (red), β-hydroxy amino acids (green) and enduracididine (blue). 
 
Nevertheless, other common structural features can still be 
seen in these peptides. As the lipid components of bacterial cell 
walls are negatively charged, antibacterial agents are typically 
cationic and amphiphilic to facilitate effective charged-mediated 
binding interactions.[34,119] For instance, the guanidine side chain 
of teixobactin and katanosin B as well as the ornithine residue of 
ramoplanin are positively charged.[83,106,120] Another evidence 
came from a study by Fletcher et al. which demonstrated that 
the positively charge pyrylium moiety of a small molecule 
inhibitor BAS00127538 15 (Figure 12) was essential in forming 
ionic interactions with the phosphate group.[58] Apart from the 
pyrylium ring, its indolene and two phenyl rings are predicted to 
interact with the hydrophobic undecaprenyl residues and the 
MurNAc of lipid II, respectively.[58,121] 
 
 
 
 
 
 
 
 
 
Figure 12. BAS00127538, a small molecule lipid II inhibitor (15). 
 
Recently, in an attempt to identify transglycosylase 
inhibitors through in silico followed by in vitro biochemical 
screens, a lipid II inhibitor was unexpectedly discovered.[122] This 
lipid II inhibitor is a tryptamine-containing molecule 16 (Figure 
13). Biological evaluation on a subset of related analogues 
showed that the replacement of the amine group with a 
guanidine moiety improved their lipid II-binding ability.[123] These 
compounds thus serve as valuable leads for further optimisation 
and development of novel low molecular weight lipid II inhibitors. 
Over the years, there has been a growing interest in peptide 
antibacterial agents over small molecules as peptides generally 
exhibit better target specificity and a lower risk of systemic 
toxicity.[124,125]  
 
 
Besides that, all of the lipid II inhibitors discussed above 
contain D-amino acids and/or non-proteinogenic amino acids 
which are often synthesised by bacteria.[126] Their presence 
confers improved in vivo protease stability to these antimicrobial 
peptides, thereby overcoming pharmacokinetic issues such as 
short half-life and poor oral bioavailability that often thwart the 
therapeutic applications of peptides with only naturally occurring 
amino acids.[127,128]  
 
 
 
 
 
 
 
Figure 13. The tryptamine-containing lead compound discovered through in 
silico screening that binds to lipid II (16). 
 
Interestingly, as pointed out by von Nussbaum et al.[106], 
teixobactin 4 is structurally similar to hypeptin 17, an octapeptide 
isolated in 1989 from a strain of Pseudomonas sp. Hypeptin also 
showed good antibacterial activity against S. aureus.[129] Apart 
from the same 13-membered ring size, hypeptin possesses 
similar shape and amino acid composition as teixobactin, with 
three L-amino acids and one D-amino acid involved in the 
formation of the cyclic ring.[106] The only major difference is that 
hypeptin has a shorter exocyclic linear peptide chain. 
Nevertheless, it can be seen from Figure 14 that the first two 
amino acids of hypeptin (Ala-D-Leu) are both aliphatic which are 
comparable to the aliphatic dipeptide in teixobactin (D-allo-Ile-
Ile), thereby suggesting their role in forming hydrophobic 
interactions with lipid II. β-Hydroxy amino acids are also a 
characteristic feature of these cyclic peptides. In fact, half of the 
amino acids of hypeptin are β-hydroxylated. These structural 
resemblances have led to suggestion that hypeptin might also 
interact with lipid II.[106]  
Amidst the excitement around teixobactin 4, there are 
concerns that resistance would ultimately emerge especially if 
the trend of inappropriate antimicrobial use remained 
widespread. Possible resistance mechanisms include secretion 
of antibiotic-modifying enzymes and thickening of bacterial cell 
wall that impedes the access of teixobactin to its lipid II target.[23] 
It is also uncertain if resistance is already in existence in 
nature.[16] However, this should not be a major concern since the 
producer of teixobactin is a Gram-negative pathogen and so it is 
unlikely to have transferred its intrinsic resistance mechanisms 
to its Gram-positive counterparts.[20,23] Additionally, it has been 
proposed that unlike other resistance mechanisms that involve 
efflux pumps and enzymes mutations, resistance to lipid II 
binders does not occur readily due to the difficulty in modifying a 
component that is biosynthesised in multiple steps.[30,130,131] As 
lipid II is a unique non-protein target that cannot be easily 
altered by simple gene mutations especially at its pyrophosphate 
and lipid portions, resistance towards teixobactin is unlikely to 
develop at least for the next few decades.[20,23,47]  
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Figure 14. Structural resemblances between teixobactin (4) and hypeptin (17) 
with the same ring size as well as similar alipathic dipeptides (circle) and β-
hydroxy amino acids (green). 
 
4. Summary and Outlook 
 
AMR is a prevalent global issue that has significant human and 
financial implications. Apart from curbing the misuse of 
antibiotics, intensive research into finding new antibiotics is of 
utmost importance to address the current unmet treatment 
needs for resistant bacterial strains. The enhanced appreciation 
of the molecular basis of cell wall biosynthetic pathways and the 
development of modern tools to explore uncultured soil bacteria 
provide hopes for discovering novel antibacterial agents.  
Lipid II has been validated as a prominent molecular target 
and various lipid II binders with substantial structural diversity 
have emerged. As great progress has been made and more 
medicinal chemistry research projects would soon unfold, the 
battle against bacterial infections might not be lost. The 
antibacterial efficacy of teixobactin especially against resistant 
strains offers promise of further clinical applications once proper 
validation studies have been carried out. However, its current 
lack of resistance could not be taken for granted and the power 
of evolution should not be underestimated as resistance might 
surface during its clinical usage period.   
Acknowledgement: We would like to acknowledge financial 
support from Vice-Chancellor’s Scholarship for Research 
Excellence, University of Nottingham (to VN). We thank Dr 
Anton Chugunov for the structure file of lipid II which we used to 
generate the figure (using PyMOL) in the frontispiece and the 
graphical abstract (table of contents). 
Keywords: lipid II inhibitors • macrocyclic peptides • antibiotics •  
[1] M. Wainwright, Mycologist 1989, 3, 21–23. 
[2] S. A. Alharbi, M. Wainwright, T. A. Alahmadi, H. Bin Salleeh, A. A. 
Faden, A. Chinnathambi, Saudi J. Biol. Sci. 2014, 21, 289–93. 
[3] A. Penesyan, M. Gillings, I. T. Paulsen, Molecules 2015, 20, 5286–
98. 
[4] N. Kardos, A. L. Demain, Appl. Microbiol. Biotechnol. 2011, 92, 
677–87. 
[5] C. M. Kunin, Ann. Intern. Med. 1993, 118, 557. 
[6] G. J. Ebrahim, J. Trop. Pediatr. 2010, 56, 141–3. 
[7] C. T. Walsh, T. A. Wencewicz, J. Antibiot. (Tokyo). 2014, 67, 7–22. 
[8] M. L. Cohen, Science 1992, 257, 1050–1055. 
[9] A. J. Alanis, Arch. Med. Res. 2005, 36, 697–705. 
[10] H. W. Boucher, G. H. Talbot, D. K. Benjamin, J. Bradley, R. J. 
Guidos, R. N. Jones, B. E. Murray, R. A. Bonomo, D. Gilbert, Clin. 
Infect. Dis. 2013, 56, 1685–94. 
[11] F. C. Tenover, Am. J. Med. 2006, 119, S3–10; discussion S62–70. 
[12] E. D. Brown, G. D. Wright, Nature 2016, 529, 336–343. 
[13] J. O’Neill, Rev. Antimicrob. Resist. 2014, 1–16. 
[14] C. A. Arias, B. E. Murray, N. Engl. J. Med. 2015, 372, 1168–70. 
[15] R. I. Aminov, Front. Microbiol. 2010, 1, 134. 
[16] L. L. Ling, T. Schneider, A. J. Peoples, A. L. Spoering, I. Engels, B. 
P. Conlon, A. Mueller, D. E. Hughes, S. Epstein, M. Jones, et al., 
Nature 2015, 517, 455–459. 
[17] J. B. Hamburger, A. J. Hoertz, A. Lee, R. J. Senturia, D. G. 
McCafferty, P. J. Loll, Proc. Natl. Acad. Sci. U. S. A. 2009, 106, 
13759–64. 
[18] K. Lewis, Nature 2012, 485, 439–40. 
[19] Y. Wang, Y. Chen, Q. Zhou, S. Huang, K. Ning, J. Xu, R. M. Kalin, S. 
Rolfe, W. E. Huang, PLoS One 2012, 7, e47530. 
[20] C. T. Kåhrström, Nat. Rev. Microbiol. 2015, 13, 126–127. 
[21] D. Nichols, N. Cahoon, E. M. Trakhtenberg, L. Pham, A. Mehta, A. 
Belanger, T. Kanigan, K. Lewis, S. S. Epstein, Appl. Environ. 
Microbiol. 2010, 76, 2445–50. 
[22] G. Wright, Nature 2015, 517, 442–4. 
[23] A. Kali, J. Clin. Diagn. Res. 2015, 9, DL01. 
[24] A. L. Koch, Clin. Microbiol. Rev. 2003, 16, 673–87. 
[25] A. Chugunov, D. Pyrkova, D. Nolde, A. Polyansky, V. Pentkovsky, R. 
Efremov, Sci. Rep. 2013, 3, 1678. 
[26] S.-T. D. Hsu, E. Breukink, E. Tischenko, M. A. G. Lutters, B. de 
Kruijff, R. Kaptein, A. M. J. J. Bonvin, N. A. J. van Nuland, Nat. 
Struct. Mol. Biol. 2004, 11, 963–7. 
[27] B. de Kruijff, V. van Dam, E. Breukink, Prostaglandins. Leukot. 
Essent. Fatty Acids 2008, 79, 117–21. 
[28] H. Harz, K. Burgdorf, J.-V. Höltje, Anal. Biochem. 1990, 190, 120–
MINIREVIEW          
 
 
 
 
 
128. 
[29] J. van Heijenoort, L. Gutmann, Proc. Natl. Acad. Sci. U. S. A. 2000, 
97, 5028–30. 
[30] E. Breukink, B. de Kruijff, Nat. Rev. Drug Discov. 2006, 5, 321–32. 
[31] S. O. Meroueh, K. Z. Bencze, D. Hesek, M. Lee, J. F. Fisher, T. L. 
Stemmler, S. Mobashery, Proc. Natl. Acad. Sci. U. S. A. 2006, 103, 
4404–9. 
[32] A. J. F. Egan, J. Biboy, I. van’t Veer, E. Breukink, W. Vollmer, Philos. 
Trans. R. Soc. B Biol. Sci. 2015, 370, 20150031. 
[33] J. Humann, L. L. Lenz, J. Innate Immun. 2009, 1, 88–97. 
[34] D. Münch, H.-G. Sahl, Biochim. Biophys. Acta 2015, 1848, 3062–
3071. 
[35] D.-J. Scheffers, M. G. Pinho, Microbiol. Mol. Biol. Rev. 2005, 69, 
585–607. 
[36] J. L. Strominger, D. J. Tipper, Am. J. Med. 1965, 39, 708–721. 
[37] L.-T. Sham, E. K. Butler, M. D. Lebar, D. Kahne, T. G. Bernhardt, N. 
Ruiz, Science 2014, 345, 220–2. 
[38] T. Mohammadi, V. van Dam, R. Sijbrandi, T. Vernet, A. Zapun, A. 
Bouhss, M. Diepeveen-de Bruin, M. Nguyen-Distèche, B. de Kruijff, 
E. Breukink, EMBO J. 2011, 30, 1425–32. 
[39] H.-W. Shih, Y.-F. Chang, W.-J. Li, F.-C. Meng, C.-Y. Huang, C. Ma, 
T.-J. R. Cheng, C.-H. Wong, W.-C. Cheng, Angew. Chem. Int. Ed. 
Engl. 2012, 51, 10123–6. 
[40] E. Breukink, B. de Kruijff, Biochim. Biophys. Acta - Biomembr. 1999, 
1462, 223–234. 
[41] S. F. Oppedijk, N. I. Martin, E. Breukink, Biochim. Biophys. Acta - 
Biomembr. 2016, 1858, 947–957. 
[42] N. E. Kramer, E. J. Smid, J. Kok, B. de Kruijff, O. P. Kuipers, E. 
Breukink, FEMS Microbiol. Lett. 2004, 239, 157–61. 
[43] D. R. Storm, J. L. Strominger, J. Biol. Chem. 1974, 249, 1823–7. 
[44] D. N. Ganchev, H. E. Hasper, E. Breukink, B. de Kruijff, 
Biochemistry 2006, 45, 6195–202. 
[45] T. Mascher, S. L. Zimmer, T.-A. Smith, J. D. Helmann, Antimicrob. 
Agents Chemother. 2004, 48, 2888–96. 
[46] A. Essig, D. Hofmann, D. Münch, S. Gayathri, M. Künzler, P. T. 
Kallio, H.-G. Sahl, G. Wider, T. Schneider, M. Aebi, J. Biol. Chem. 
2014, 289, 34953–64. 
[47] B. B. Bonev, E. Breukink, E. Swiezewska, B. De Kruijff, A. Watts, 
FASEB J. 2004, 18, 1862–9. 
[48] T.-J. R. Cheng, M.-T. Sung, H.-Y. Liao, Y.-F. Chang, C.-W. Chen, 
C.-Y. Huang, L.-Y. Chou, Y.-D. Wu, Y.-H. Chen, Y.-S. E. Cheng, et 
al., Proc. Natl. Acad. Sci. U. S. A. 2008, 105, 431–6. 
[49] H.-W. Shih, K.-T. Chen, T.-J. R. Cheng, C.-H. Wong, W.-C. Cheng, 
Org. Lett. 2011, 13, 4600–3. 
[50] E. Breukink, H. E. van Heusden, P. J. Vollmerhaus, E. Swiezewska, 
L. Brunner, S. Walker, A. J. R. Heck, B. de Kruijff, J. Biol. Chem. 
2003, 278, 19898–903. 
[51] B. Schwartz, J. A. Markwalder, Y. Wang, J. Am. Chem. Soc. 2001, 
123, 11638–11643. 
[52] M. S. VanNieuwenhze, S. C. Mauldin, M. Zia-Ebrahimi, B. E. Winger, 
W. J. Hornback, S. L. Saha, J. A. Aikins, L. C. Blaszczak, J. Am. 
Chem. Soc. 2002, 124, 3656–3660. 
[53] L.-Y. Huang, S.-H. Huang, Y.-C. Chang, W.-C. Cheng, T.-J. R. 
Cheng, C.-H. Wong, Angew. Chem. Int. Ed. Engl. 2014, 53, 8060–5. 
[54] J. van Heijenoort, Microbiol. Mol. Biol. Rev. 2007, 71, 620–35. 
[55] M. C. Lo, H. Men, A. Branstrom, J. Helm, N. Yao, R. Goldman, S. 
Walker, J. Amer. Chem. Soc. 2000, 122, 3540–3541. 
[56] H. Brötz, M. Josten, I. Wiedemann, U. Schneider, F. Götz, G. 
Bierbaum, H. G. Sahl, Mol. Microbiol. 1998, 30, 317–327. 
[57] T. Schneider, H.-G. Sahl, Int. J. Med. Microbiol. 2010, 300, 161–9. 
[58] S. Fletcher, W. Yu, J. Huang, S. M. Kwasny, J. Chauhan, T. J. 
Opperman, A. D. MacKerell, E. P. H. de Leeuw, Drug Des. Devel. 
Ther. 2015, 9, 2383–94. 
[59] B. P. Howden, J. K. Davies, P. D. R. Johnson, T. P. Stinear, M. L. 
Grayson, Clin. Microbiol. Rev. 2010, 23, 99–139. 
[60] J. C. Barna, D. H. Williams, Annu. Rev. Microbiol. 1984, 38, 339–57. 
[61] P. E. Reynolds, Eur. J. Clin. Microbiol. Infect. Dis. 1989, 8, 943–950. 
[62] D. Münch, I. Engels, A. Müller, K. Reder-Christ, H. Falkenstein-Paul, 
G. Bierbaum, F. Grein, G. Bendas, H.-G. Sahl, T. Schneider, 
Antimicrob. Agents Chemother. 2015, 59, 772–81. 
[63] C. G. Marshall, I. A. Lessard, I. Park, G. D. Wright, Antimicrob. 
Agents Chemother. 1998, 42, 2215–20. 
[64] P. Courvalin, Clin. Infect. Dis. 2006, 42, S25–S34. 
[65] C. T. Walsh, S. L. Fisher, I.-S. Park, M. Prahalad, Z. Wu, Chem. Biol. 
1996, 3, 21–28. 
[66] T. D. H. Bugg, G. D. Wright, S. Dutka-Malen, M. Arthur, P. Courvalin, 
C. T. Walsh, Biochemistry 1991, 30, 10408–10415. 
[67] F. Van Bambeke, Curr. Opin. Investig. Drugs 2006, 7, 740–9. 
[68] P. K. Linden, Expert Rev. Anti. Infect. Ther. 2008, 6, 917–928. 
[69] S. J. Kim, L. Cegelski, D. Stueber, M. Singh, E. Dietrich, K. S. E. 
Tanaka, T. R. Parr, A. R. Far, J. Schaefer, J. Mol. Biol. 2008, 377, 
281–93. 
[70] L. D. Saravolatz, J. Pawlak, L. B. Johnson, Int. J. Antimicrob. 
Agents 2010, 36, 69–72. 
[71] F. F. Arhin, D. C. Draghi, C. M. Pillar, T. R. Parr, G. Moeck, D. F. 
Sahm, Antimicrob. Agents Chemother. 2009, 53, 4762–71. 
[72] S.-T. D. Hsu, E. Breukink, G. Bierbaum, H.-G. Sahl, B. de Kruijff, R. 
Kaptein, N. A. J. van Nuland, A. M. J. J. Bonvin, J. Biol. Chem. 2003, 
278, 13110–7. 
[73] M. R. Islam, J.-I. Nagao, T. Zendo, K. Sonomoto, Biochem. Soc. 
Trans. 2012, 40, 1528–33. 
[74] A. Guder, I. Wiedemann, H. G. Sahl, Biopolymers 2000, 55, 62–73. 
[75] N. Schnell, K.-D. Entian, U. Schneider, F. Götz, H. Zähner, R. 
Kellner, G. Jung, Nature 1988, 333, 276–278. 
[76] G. Jung, Angew. Chemie Int. Ed. English 1991, 30, 1051–1068. 
[77] A. Arguelles Arias, M. Ongena, B. Devreese, M. Terrak, B. Joris, P. 
Fickers, PLoS One 2013, 8, e83037. 
[78] C. van Kraaij, W. M. de Vos, R. J. Siezen, O. P. Kuipers, Nat. Prod. 
Rep. 1999, 16, 575–87. 
[79] W. C. Chan, M. Leyland, J. Clark, H. M. Dodd, L.-Y. Lian, M. J. 
Gasson, B. W. Bycroft, G. C. K. Roberts, FEBS Lett. 1996, 390, 
129–132. 
[80] H. E. Hasper, B. de Kruijff, E. Breukink, Biochemistry 2004, 43, 
11567–75. 
[81] I. Wiedemann, E. Breukink, C. van Kraaij, O. P. Kuipers, G. 
Bierbaum, B. de Kruijff, H. G. Sahl, J. Biol. Chem. 2001, 276, 1772–
9. 
[82] T. Koopmans, T. M. Wood, P. ’t Hart, L. H. J. Kleijn, A. P. A. 
MINIREVIEW          
 
 
 
 
 
Hendrickx, R. J. L. Willems, E. Breukink, N. I. Martin, J. Am. Chem. 
Soc. 2015, 137, 9382–9. 
[83] A. Ruzin, G. Singh, A. Severin, Y. Yang, R. G. Dushin, A. G. 
Sutherland, A. Minnick, M. Greenstein, M. K. May, D. M. Shlaes, et 
al., Antimicrob. Agents Chemother. 2004, 48, 728–38. 
[84] R. Bauer, L. M. T. Dicks, Int. J. Food Microbiol. 2005, 101, 201–216. 
[85] Y. Hu, J. S. Helm, L. Chen, X.-Y. Ye, S. Walker, J. Am. Chem. Soc. 
2003, 125, 8736–7. 
[86] X. Yin, T. M. Zabriskie, Microbiology 2006, 152, 2969–2983. 
[87] X. Fang, K. Tiyanont, Y. Zhang, J. Wanner, D. Boger, S. Walker, 
Mol. BioSyst. 2006, 2, 69–76. 
[88] P. Cudic, J. K. Kranz, D. C. Behenna, R. G. Kruger, H. Tadesse, A. 
J. Wand, Y. I. Veklich, J. W. Weisel, D. G. McCafferty, Proc. Natl. 
Acad. Sci. U. S. A. 2002, 99, 7384–9. 
[89] T. Ganz, Nat. Rev. Immunol. 2003, 3, 710–20. 
[90] E. de Leeuw, C. Li, P. Zeng, C. Li, M. Diepeveen-de Buin, W.-Y. Lu, 
E. Breukink, W. Lu, FEBS Lett. 2010, 584, 1543–8. 
[91] T. Schneider, T. Kruse, R. Wimmer, I. Wiedemann, V. Sass, U. Pag, 
A. Jansen, A. K. Nielsen, P. H. Mygind, D. S. Raventós, et al., 
Science 2010, 328, 1168–72. 
[92] P. H. Mygind, R. L. Fischer, K. M. Schnorr, M. T. Hansen, C. P. 
Sönksen, S. Ludvigsen, D. Raventós, S. Buskov, B. Christensen, L. 
De Maria, et al., Nature 2005, 437, 975–80. 
[93] J. S. Oeemig, C. Lynggaard, D. H. Knudsen, F. T. Hansen, K. D. 
Nørgaard, T. Schneider, B. S. Vad, D. H. Sandvang, L. A. Nielsen, 
S. Neve, et al., J. Biol. Chem. 2012, 287, 42361–72. 
[94] M. Wilmes, B. P. A. Cammue, H.-G. Sahl, K. Thevissen, Nat. Prod. 
Rep. 2011, 28, 1350–8. 
[95] G. Bierbaum, H. G. Sahl, Arch. Microbiol. 1985, 141, 249–54. 
[96] H. J. Rogers, C. W. Forsberg, J. Bacteriol. 1971, 108, 1235–43. 
[97] L. Han, A. W. Schwabacher, G. R. Moran, N. R. Silvaggi, 
Biochemistry 2015, 54, 7029–7040. 
[98] H. He, R. T. Williamson, B. Shen, E. I. Graziani, H. Y. Yang, S. M. 
Sakya, P. J. Petersen, G. T. Carter, J. Am. Chem. Soc. 2002, 124, 
9729–9736. 
[99] Y. E. Jad, G. A. Acosta, T. Naicker, M. Ramtahal, A. El-Faham, T. 
Govender, H. G. Kruger, B. G. De La Torre, F. Albericio, Org. Lett. 
2015, 17, 6182–6185. 
[100] L. M. De Leon Rodriguez, A. J. Weidkamp, M. A. Brimble, Org. 
Biomol. Chem. 2015, 13, 6906–6921. 
[101] C. J. White, A. K. Yudin, Nat. Chem. 2011, 3, 509–24. 
[102] L. Sanière, L. Leman, J.-J. Bourguignon, P. Dauban, R. H. Dodd, 
Tetrahedron 2004, 60, 5889–5897. 
[103] W. Craig, J. Chen, D. Richardson, R. Thorpe, Y. Yuan, Org. Lett. 
2015, 17, 4620–4623. 
[104] D. E. Olson, J. Y. Su, D. A. Roberts, J. Du Bois, J. Am. Chem. Soc. 
2014, 1–4. 
[105] S. Tsuji, K. Shoichi, T. Shiba, Chem. Lett. 1975, 1281–1284. 
[106] F. von Nussbaum, R. D. Süssmuth, Angew. Chemie - Int. Ed. 2015, 
54, 6684–6. 
[107] S. J. Kim, M. Singh, A. Wohlrab, T.-Y. Yu, G. J. Patti, R. D. 
O’Connor, M. VanNieuwenhze, J. Schaefer, Biochemistry 2013, 52, 
1973–9. 
[108] A. Thakkar, T. B. Trinh, D. Pei, ACS Comb. Sci. 2013, 15, 120–129. 
[109] P. Cudic, D. C. Behenna, J. K. Kranz, R. G. Kruger, A. J. Wand, Y. I. 
Veklich, J. W. Weisel, D. G. McCafferty, Chem. Biol. 2002, 9, 897–
906. 
[110] M.-C. Wu, M. Q. Styles, B. J. C. Law, A.-W. Struck, L. Nunns, J. 
Micklefield, Microbiology 2015, 161, 1338–47. 
[111] M. P. Singh, P. J. Petersen, W. J. Weiss, J. E. Janso, S. W. 
Luckman, E. B. Lenoy, P. A. Bradford, R. T. Testa, M. Greenstein, 
Antimicrob. Agents Chemother. 2003, 47, 62–69. 
[112] M. Adinolfi, D. Giacomini, A. Iadonisi, A. Quintavalla, S. Valerio, 
European J. Org. Chem. 2008, 2008, 2895–2899. 
[113] R. S. Babu, S. R. Guppi, G. A. O’Doherty, Org. Lett. 2006, 8, 1605–
8. 
[114] K. S. Olivier, M. S. Van Nieuwenhze, Org. Lett. 2010, 12, 1680–3. 
[115] R. G. Dushin, T.-Z. Wang, P.-E. Sum, H. He, A. G. Sutherland, J. S. 
Ashcroft, E. I. Graziani, F. E. Koehn, P. A. Bradford, P. J. Petersen, 
et al., J. Med. Chem. 2004, 47, 3487–90. 
[116] P.-E. Sum, D. How, N. Torres, H. Newman, P. J. Petersen, T. S. 
Mansour, Bioorg. Med. Chem. Lett. 2003, 13, 2607–2610. 
[117] P. J. Petersen, T. Z. Wang, R. G. Dushin, P. A. Bradford, Antimicrob. 
Agents Chemother. 2004, 48, 739–46. 
[118] S. Fuse, H. Koinuma, A. Kimbara, M. Izumikawa, Y. Mifune, H. He, 
K. Shin-ya, T. Takahashi, T. Doi, J. Am. Chem. Soc. 2014, 136, 
12011–7. 
[119] D. G. Brown, T. L. May-Dracka, M. M. Gagnon, R. Tommasi, J. Med. 
Chem. 2014, 57, 10144–61. 
[120] M. Cheng, J. X. Huang, S. Ramu, M. S. Butler, M. A. Cooper, 
Antimicrob. Agents Chemother. 2014, 58, 6819–6827. 
[121] K. M. Varney, A. M. J. J. Bonvin, M. Pazgier, J. Malin, W. Yu, E. 
Ateh, T. Oashi, W. Lu, J. Huang, M. Diepeveen-de Buin, et al., 
PLoS Pathog. 2013, 9, e1003732. 
[122] A. Derouaux, S. Turk, N. K. Olrichs, S. Gobec, E. Breukink, A. 
Amoroso, J. Offant, J. Bostock, K. Mariner, I. Chopra, et al., 
Biochem. Pharmacol. 2011, 81, 1098–105. 
[123] I. Sosič, M. Anderluh, M. Sova, M. Gobec, I. Mlinarič Raščan, A. 
Derouaux, A. Amoroso, M. Terrak, E. Breukink, S. Gobec, J. Med. 
Chem. 2015, 58, 9712–21. 
[124] D. J. Craik, D. P. Fairlie, S. Liras, D. Price, Chem. Biol. Drug Des. 
2013, 81, 136–47. 
[125] K. Fosgerau, T. Hoffmann, Drug Discov. Today 2014, 20, 122–128. 
[126] A. D. Radkov, L. A. Moe, Appl. Microbiol. Biotechnol. 2014, 98, 
5363–5374. 
[127] L. Gentilucci, R. De Marco, L. Cerisoli, Curr. Pharm. Des. 2010, 16, 
3185–203. 
[128] D. P. McGregor, Curr. Opin. Pharmacol. 2008, 8, 616–9. 
[129] H. Hinoo, T. Hattori, Y. Kimura, T. Yoshida, J. Shoji, K. Hirooka, J. 
Antibiot. (Tokyo). 1989, 42, 1460–1464. 
[130] T. J. Oman, T. J. Lupoli, T. S. A. Wang, D. Kahne, S. Walker, W. a. 
Van Der Donk, J. Am. Chem. Soc. 2011, 133, 17544–17547. 
[131] T. Schneider, H.-G. Sahl, Curr. Opin. Investig. Drugs 2010, 11, 157–
64. 
 
MINIREVIEW          
 
 
 
 
 
Entry for the Table of Contents (Please choose one layout) 
 
Layout 1: 
 
MINIREVIEW 
Tackle Bac! Lipid II inhibitors, such as 
the recently discovered teixobactin 
and mannopeptimycin ε, offers the 
promise of solving the global bacterial 
infection crisis. 
   Vivian Ng and Weng C. Chan* 
Page No. – Page No. 
New found hope for antibiotic 
discovery: lipid II inhibitors 
 
  
 
 
Layout 2: 
MINIREVIEW 
Text for Table of Contents 
 Author(s), Corresponding Author(s)* 
Page No. – Page No. 
Title 
 
 
 
 
((Insert TOC Graphic here)) 
 
